Abeona Therapeutics Inc

Announcement: ABEO 8-K Special Filing

Part 1: Analysis of the Company's Performance During the Period

Abeona Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for life-threatening diseases. The company's lead clinical program is EB-101, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (“RDEB”).

The topline data reported from the VIITAL™ study evaluating the efficacy, safety and tolerability of EB-101 showed statistically significant and clinically meaningful improvements in wound healing and pain reduction in large chronic RDEB wounds. This positive data led the company to intend to submit a Biologics License Application (“BLA”) for EB-101 to the U.S. Food and Drug Administration (“FDA”) in late second quarter of 2023 or early third quarter of 2023. This potential approval of the drug can be a significant milestone for the company and its investors, as EB-101 has the potential to provide meaningful improvements in the quality of life for RDEB patients.

In addition to EB-101, Abeona also has a portfolio of adeno-associated virus (“AAV”) based gene therapies designed to treat ophthalmic diseases. The company has scheduled pre-Investigational New Drug (“IND”) application meetings with the FDA in the second quarter of 2023 to gain alignment on IND enabling studies. This development program has shown promising results in mouse disease models, and the company is scheduled to present new preclinical data from these three programs at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (“ASGCT”) taking place from May 16-20, 2023 in Los Angeles, CA.

Furthermore, Abeona has been preparing its current Good Manufacturing Practices (“cGMP”) commercial facility in Cleveland, Ohio for manufacturing EB-101 drug product to support its planned BLA filing to the FDA. The company has continued to engage with stakeholders across the healthcare system, including public and private payors, and healthcare providers to better understand market access and potential pricing for EB-101. This commercial preparation shows the company's commitment to bringing its potentially life-changing therapies to patients while also considering the affordability and accessibility of the treatments.

Part 2: Forward Looking Analysis 

Abeona Therapeutics has a promising future, especially if EB-101 is approved for the treatment of RDEB. The company plans to submit a BLA to the FDA in late second quarter of 2023 or early third quarter of 2023. Upon potential approval, the company will focus on commercializing its product while considering patient affordability and accessibility. The preclinical pipeline for ophthalmic diseases is also an area for potential revenue growth, as positive results from ongoing studies may lead to further clinical trials and eventual regulatory approval.

The company's competitive position will depend on the efficacy, safety, and affordability of its treatments, as well as the number of competitors in the market. Although there is no cure for RDEB, there are other treatments available to treat the symptoms, which may impact the potential market for EB-101 if approved. The ophthalmic gene therapy market is also a competitive space, with established players like Spark Therapeutics and Roche.

Quotes from the company's CEO and management show an optimistic outlook for the company's future, including CEO Michael Amoroso stating, "We are excited about the progress we continue to make as we work to develop our innovative medicines and bring them to patients in need." The company's continued engagement with stakeholders across the healthcare system also highlights its commitment to making its treatments accessible to patients.

It is worth noting that, as a clinical-stage biopharmaceutical company, Abeona Therapeutics has yet to generate any revenue from product sales. Investors should also be aware of the risks involved in investing in a company that is still in the development stage, including the possibility of clinical trial failures and regulatory hurdles. However, if the company is successful in bringing its treatments to market, it has the potential for significant revenue growth.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Abeona Therapeutics submits BLA for RDEB treatment

Abeona Therapeutics, a clinical-stage biopharmaceutical company, reported its first-quarter financial results for 2023, which shows decreased costs compared to the same period in 2022. Its net loss in Q1 2023 was $9.1 million, or $0.54 loss per common share, compared to a net loss of $22.0 million, or $3.80 loss per common share, in Q1 2022. Abeona remains focused on Biologics License Application (BLA) submission for its investigational autologous, engineered cell therapy, EB-101, for recessive dystrophic epidermolysis bullosa (RDEB) and anticipates submitting BLA in late 2Q or early 3Q 2023. The company has also submitted a request for pre-BLA meeting. Abeona also presented additional Phase 3 VIITAL study results at the International Societies for Investigative Dermatology 2023 Meeting, further highlighting EB-101 value proposition in RDEB. Additionally, it has several presentations on animal proof-of-concept data from its AAV ophthalmology program at upcoming 26th Annual Meeting of American Society of Gene & Cell Therapy. Abeona has reiterated cash runway guidance into Q3 2024, which is beyond anticipated timing for EB-101 BLA potential approval. The current cash and cash equivalents, restricted cash, and short-term investments are estimated to be sufficient resources to fund operations until Q3 2024, according to the financial report. The company will hold a conference call and webcast on May 23, 2023, to discuss its first-quarter and recent portfolio updates and data presentations at the ISID and ASGCT meetings.

Form 8-K - Current report - Item 2.02 Item 9.01

$ABEO Reports Decreased Costs and Progress Towards BLA Submission for its EB-101 Therapy for RDEB in Q1 2023 Financial Results

INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Announcement: ABEO 10-K/A Special Filing Amendment

Abeona Therapeutics has revealed affirmative outcomes for its Phase 3 VIITAL study of EB-101 in recessive dystrophic epidermolysis bullosa. According to CEO Vish Seshadri, "We are of the opinion that the VIITAL study results showcase the potential value of EB-101". In line with this, the company has expressed plans to put forward a Biologics License Application to the FDA in late Q2 or early Q3 of 2023 by leveraging these results. Additionally, Abeona is continuing to make progress with adeno-associated virus (AAV)-based gene therapy options for Stargardt Disease, X-linked Retinoschisis, and Autosomal Dominant Optic Atrophy in preparation for IND studies. The company's revenues for 2022 amounted to $1.4 million, with resources enough to support operations until Q3 2024, as estimated by Abeona. As a professional financial analyst, this information provides a glimpse of Abeona's current activities, potential for future growth, and overall financial standing.

Announcement: ABEO 8-K Special Filing

Announcement: ABEO 8-K Special Filing

Abeona Therapeutics submits BLA for RDEB treatment

Abeona Therapeutics submits BLA for RDEB treatment

$ABEO Reports Decreased Costs and Progress Towards BLA Submission for its EB-101 Therapy for RDEB in Q1 2023 Financial Results

$ABEO Reports Decreased Costs and Progress Towards BLA Submission for its EB-101 Therapy for RDEB in Q1 2023 Financial Results

Announcement: ABEO 8-K Special Filing

Announcement: ABEO 8-K Special Filing

Announcement: ABEO 10-K/A Special Filing Amendment

Announcement: ABEO 10-K/A Special Filing Amendment

$ABEO reports positive Phase 3 results and plans for BLA submission

$ABEO reports positive Phase 3 results and plans for BLA submission